查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1186540

红生物科技的全球市场 - 现状分析与预测(2022年～2028年)

Red Biotechnology Market: Current Analysis and Forecast (2022-2028)
出版日期: | 出版商: UnivDatos Market Insights Pvt Ltd | 英文 140 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

全球红生物科技的市场规模在预测期间内预计将以约6％大幅成长。罕见疾病的增加、病毒突变的爆发、政府和私人组织对生物製品行业的投资增加等都是促进市场增长的因素。

本报告提供全球红生物科技市场相关调查分析，市场规模与预测分析，主要趋势和机会，企业简介等资讯。

目录

第1章 市场简介

第2章 调查手法·前提条件

第3章 市场摘要

第4章 摘要整理

第5章 红生物科技市场上COVID-19影响

第6章 红生物科技市场收益(2020年～2028年)

第7章 市场考察:各用途

  • 生物医药品的生产
  • 基因治疗
  • 药物基因体学
  • 遗传基因检验
  • 其他

第8章 市场考察:各产品类型

  • 基因重组医药品
  • 人体疫苗
  • 血液製剂
  • 诊断剂
  • 个人化医疗
  • 其他

第9章 市场考察:各地区

  • 北美
    • 美国
    • 加拿大
    • 其他的北美
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他的欧洲
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他的亚太地区
  • 其他地区

第10章 红生物科技的市场动态

  • 推动市场要素
  • 市场课题
  • 影响的分析

第11章 红生物科技市场机会

第12章 红生物科技市场趋势

第13章 需求端和供应端的分析

  • 需求端分析
  • 供应端分析

第14章 价值链分析

第15章 竞争模式

  • 竞争情形
    • 波特的五力分析

第16章 企业简介

  • Pfizer Inc.
  • AstraZeneca PLC
  • F. Hoffmann-La Roche Ltd
  • Celgene Corporation
  • Takeda Pharmaceutical Company Limited
  • Biogen Inc.
  • Amgen Inc.
  • Gilead Sciences Inc.
  • Merck & Co. Inc.
  • CSL Limited

第17章 免责声明

简介目录
Product Code: UMME211346

The global red biotechnology market is expected to grow at a significant rate of around 6% during the forecast period. Biopharmaceuticals are complex medicines made from living cells or organisms, often produced using cutting-edge biotechnological methods. The reliability and safety of biopharmaceutical products along with their ability to treat rare diseases are among the important factors responsible for the market growth of the biopharmaceutical industry. Furthermore, the rising number of orphan diseases, the occurrence of mutation in the viruses, and increasing investments in the biologics industry by government & private organizations are also contributing factors to the market growth of red biotechnology. For instance, in July 2022, vaccine maker Biological E announced its expansion plans for investment of over Rs 1,800 crore.

Pfizer Inc., AstraZeneca Plc, F. Hoffmann-La Roche Ltd, Celgene Corporation, Takeda Pharmaceutical Company Limited, Biogen Inc., Amgen Inc., Gilead Sciences Inc., Merck & Co. Inc., and CSL Limited are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

 

Insights Presented in the Report:

"Amongst Application, pharmacogenomics category to witness higher CAGR during the forecast period"

Based on the application, the market has been categorized into biopharmaceutical production, gene therapy, pharmacogenomics, genetic testing, and others. The pharmacogenomics category is expected to witness a higher CAGR during the forecast period. The rising number of genetic disorders along with the increasing number of autoimmune disorders and the rising biotechnology industry in developing nations is responsible for the segmental growth of pharmacogenomics.

"Amongst Product Type, human vaccines to hold a significant share in the market in 2020"

Based on the product type, the market has been categorized into gene recombinant drugs, human vaccines, blood products, diagnostics reagents, personalized medicines, and others. Among them, the human vaccines segment is expected to have significant growth in the market during the forecast period. The rising government efforts to increase vaccination along with vaccines provide long-term solutions against the disease is attributed to the growth of the market. For instance, as per the national health mission, Universal Immunization Program (UIP) is one of the largest public health programs targeting close of 2.67 crore newborns and 2.9 crore pregnant women annually.

"North America to hold a dominant share in the market"

For a better understanding of the market adoption of the red biotechnology industry, the market is analyzed based on its worldwide presence in the countries such as North America (United States, Canada, and the Rest of North America), Europe (Germany, France, Italy, Spain, United Kingdom and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, and Rest of APAC), and Rest of World. In 2020, North America held a significant share of the global red biotechnology market. This is mainly attributed to the presence of major economies along with the higher R&D investment in the rising biotechnology industry in the region. Furthermore, the launch of various treatment and biopharmaceutical drugs is also an important reason for the considerable growth of the regional growth of the red biotechnology industry. For instance, in June 2021, Jazz Pharmaceuticals plc announced the U.S. Food and Drug Administration (FDA) approval of Rylaze™ for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) in pediatric and adult patients who have developed hypersensitivity to E. coli-derived asparaginase.

Reasons to buy this report:

The study includes market sizing and forecasting analysis validated by authenticated key industry experts.

The report presents a quick review of overall industry performance at one glance.

The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments.

Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.

The study comprehensively covers the market across different segments.

Deep dive regional level analysis of the industry.

Customization Options:

The global red biotechnology market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

  • 1.1. Market Definitions
  • 1.2. Main Objective
  • 1.3. Stakeholders
  • 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1. Research Process of the Red Biotechnology Market
  • 2.2. Research Methodology of the Red Biotechnology Market
  • 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE RED BIOTECHNOLOGY MARKET

6 RED BIOTECHNOLOGY MARKET REVENUE (USD BN), 2020-2028F

7 MARKET INSIGHTS BY APPLICATION

  • 7.1. Biopharmaceutical Production
  • 7.2. Gene therapy
  • 7.3. Pharmacogenomics
  • 7.4. Genetic Testing
  • 7.5. Others

8 MARKET INSIGHTS BY PRODUCT TYPE

  • 8.1. Gene Recombinant Drugs
  • 8.2. Human Vaccines
  • 8.3. Blood Products
  • 8.4. Diagnostics Reagents
  • 8.5. Personalized Medicines
  • 8.6. Others

9 MARKET INSIGHTS BY REGION

  • 9.1. North America
    • 9.1.1. U.S.
    • 9.1.2. Canada
    • 9.1.3. Rest of North America
  • 9.2. Europe
    • 9.2.1. Germany
    • 9.2.2. U.K.
    • 9.2.3. France
    • 9.2.4. Italy
    • 9.2.5. Spain
    • 9.2.6. Rest of Europe
  • 9.3. Asia-Pacific
    • 9.3.1. China
    • 9.3.2. Japan
    • 9.3.3. India
    • 9.3.4. Rest of Asia-Pacific
  • 9.4. Rest of World

10 RED BIOTECHNOLOGY MARKET DYNAMICS

  • 10.1. Market Drivers
  • 10.2. Market Challenges
  • 10.3. Impact Analysis

11 RED BIOTECHNOLOGY MARKET OPPORTUNITIES

12 RED BIOTECHNOLOGY MARKET TRENDS

13 DEMAND AND SUPPLY-SIDE ANALYSIS

  • 13.1. Demand Side Analysis
  • 13.2. Supply Side Analysis

14 VALUE CHAIN ANALYSIS

15 COMPETITIVE SCENARIO

  • 15.1. Competitive Landscape
    • 15.1.1. Porters Fiver Forces Analysis

16 COMPANY PROFILED

  • 16.1. Pfizer Inc.
  • 16.2. AstraZeneca PLC
  • 16.3. F. Hoffmann-La Roche Ltd
  • 16.4. Celgene Corporation
  • 16.5. Takeda Pharmaceutical Company Limited
  • 16.6. Biogen Inc.
  • 16.7. Amgen Inc.
  • 16.8. Gilead Sciences Inc.
  • 16.9. Merck & Co. Inc.
  • 16.10. CSL Limited

17 DISCLAIMER